Teriparatide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Teriparatide

Also known as: PTH 1-34, PTH(1-34), rhPTH 1-34, recombinant human parathyroid hormone 1-34, Forteo

Anabolic bone agent; recombinant parathyroid hormone peptide fragment (amino acids 1–34)

Research chemicalLast updated: October 31, 2026Based on 41 peer-reviewed studies

What it is

Teriparatide is the active ingredient in Forteo, an FDA-approved injectable treatment for osteoporosis in people at high risk of bone fractures. It works by stimulating bone-building cells to add new bone tissue. Prescription-only; approved for osteoporosis; also studied for fracture healing and bone repair.

The scientific side

Teriparatide is the 1–34 amino-acid fragment of human parathyroid hormone (PTH). It binds to the PTH1 receptor (PTH1R) and, when administered intermittently, activates the Wnt signaling, cAMP/PKA, cAMP/PKC, and RANKL/RANK/OPG pathways, acting directly on mesenchymal stem cells, osteoblast-lineage cells, and osteocytes to promote bone formation. Intermittent dosing stimulates both remodeling-based bone formation (within active remodeling sites) and modeling-based bone formation (on previously inactive bone surfaces), yielding net increases in bone mineral density. Continuous administration, in contrast, promotes bone resorption rather than formation. In preclinical osteoarthritis models, teriparatide suppressed TNF-α–mediated MMP-13 overexpression, reducing synovial inflammation and cartilage degradation. In a rat cerebral ischemia model, teriparatide promoted angiogenesis via the AC/PKA signaling pathway, upregulating Ang-1 expression.

Class: Anabolic bone agent; recombinant parathyroid hormone peptide fragment (amino acids 1–34)

Administration & storage

Administration
Subcutaneous injection — daily (PMID: 35900607PMID: 27374026PMID: 40500389PMID: 36424580)Subcutaneous injection — weekly (PMID: 37529188PMID: 31429640)Subcutaneous continuous infusion via Omnipod® insulin pump device (PMID: 34984624)Thrice-daily subcutaneous injections — described in refractory hypoparathyroidism prior to pump use (PMID: 34984624)In vitro administration at 100 ng/mL in cell culture (PMID: 36371341)
Storage
Storage conditions for teriparatide are not described in the reviewed abstracts.
Cautions
Hypercalcemia has been reported with teriparatide use, including prolonged and severe cases (serum calcium >3.0 mmol/l); routine serum calcium monitoring during therapy is important, particularly in patients at risk (e.g., low body weight) (PMID: 40500389, PMID: 38613637).,Calciphylaxis (a rare, potentially fatal small-vessel occlusive disease) has been reported in association with teriparatide, predominantly in patients with multiple risk factors; median time-to-onset was 3.5 months after initiation.,Cardiac arrhythmias (including atrial tachycardia and atrial fibrillation) have been reported in teriparatide users based on pharmacovigilance data and case reports (PMID: 36543300, PMID: 29487102).,Teriparatide carries a warning (based on pre-approval animal studies) regarding an increased risk of osteosarcoma; its use is generally avoided in patients with risk factors for osteosarcoma, including prior radiotherapy.,Treatment discontinuation due to adverse events (including dizziness, hypercalcemia, elevated alkaline phosphatase, and arthralgia) appears more common with teriparatide than with bisphosphonates in some comparative studies (PMID: 38064598, PMID: 35900607).,BMD gains from teriparatide are not sustained after treatment discontinuation without subsequent antiresorptive therapy; less than half of patients in one real-world study received antiresorptive therapy after stopping teriparatide (PMID: 34490946, PMID: 29996965).,Sterile technique is essential for all injectable preparations to prevent infection at the injection site.

Legal & regulatory status

US FDA

FDA-approved (Forteo) for postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and for glucocorticoid-induced…

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification